Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 extension trial of glepaglutide in short bowel syndrome
NL-OMON55754Phase 3Recruiting
- Sponsor
- Zealand Pharma
- Start
- Apr 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) comparing Glepaglutide with Placebo (2 arms). Started Apr 2020; status: recruiting.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON55754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55754.